Oragenics Files 8-K on Feb 5, Confirms NYSE American Listing
Ticker: OGEN · Form: 8-K · Filed: Feb 5, 2024 · CIK: 1174940
Complexity: simple
Sentiment: neutral
Topics: compliance, regulatory-filing, corporate-governance
TL;DR
**Oragenics filed a routine 8-K, confirming its NYSE American listing.**
AI Summary
Oragenics, Inc. filed an 8-K on February 5, 2024, indicating an 'Other Event' and 'Financial Statements and Exhibits.' This filing primarily serves to update the public record regarding the company's current status and its listing on the NYSE American under the trading symbol OGEN. For investors, this matters because it confirms the company's continued compliance with SEC reporting requirements and its active trading status, which is fundamental for liquidity and transparency.
Why It Matters
This filing confirms Oragenics' ongoing compliance with SEC regulations and its listing on the NYSE American, which is crucial for maintaining investor confidence and market accessibility.
Risk Assessment
Risk Level: low — This 8-K is a standard procedural filing with no new material financial or operational information that would introduce significant risk.
Analyst Insight
A smart investor would note this as a routine compliance filing, confirming Oragenics' continued listing and reporting, but would look for more substantive filings for investment decisions.
Key Players & Entities
- Oragenics, Inc. (company) — the registrant filing the 8-K
- NYSE American (company) — the exchange where Oragenics' Common Stock is registered
- OGEN (company) — the trading symbol for Oragenics' Common Stock
- February 5, 2024 (date) — the date of the earliest event reported and filing date
FAQ
What is the purpose of this 8-K filing by Oragenics, Inc.?
The 8-K filing by Oragenics, Inc. on February 5, 2024, is categorized under 'Other Events' and 'Financial Statements and Exhibits,' primarily serving to update the public record and confirm its status as a registrant with securities listed on an exchange.
On what date was the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing is February 5, 2024.
What is the trading symbol and exchange for Oragenics, Inc.'s Common Stock?
Oragenics, Inc.'s Common Stock trades under the symbol OGEN on the NYSE American exchange.
What is Oragenics, Inc.'s business address?
Oragenics, Inc.'s business address is 1990 Main Street, Suite 750, Sarasota, FL 34236.
Is Oragenics, Inc. considered an emerging growth company according to this filing?
The filing includes checkboxes for whether the registrant is an emerging growth company, but none are marked, indicating that the filing does not explicitly state Oragenics, Inc. is an emerging growth company.
Filing Stats: 436 words · 2 min read · ~1 pages · Grade level 11 · Accepted 2024-02-05 08:00:23
Filing Documents
- form8-k.htm (8-K) — 41KB
- ex99-1.htm (EX-99.1) — 14KB
- 0001493152-24-004887.txt ( ) — 226KB
- ogen-20240205.xsd (EX-101.SCH) — 3KB
- ogen-20240205_lab.xml (EX-101.LAB) — 33KB
- ogen-20240205_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 5 th day of February 2024. ORAGENICS, INC. (Registrant) BY: /s/Janet Huffman Janet Huffman Chief Financial Officer